Anzeige
Mehr »
Samstag, 21.03.2026 - Börsentäglich über 12.000 News
Drohnen statt Panzer: Beginnt hier der nächste Milliarden-Superzyklus?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W1ZU | ISIN: US00770C1018 | Ticker-Symbol: OXQ1
Tradegate
20.03.26 | 15:42
1,780 Euro
+2,89 % +0,050
1-Jahres-Chart
ARQ INC Chart 1 Jahr
5-Tage-Chart
ARQ INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,7101,73020.03.
1,6901,76020.03.

Aktuelle News zur ARQ Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.03.Canaccord cuts Arq stock price target on GAC production pause4
10.03.Clear Street cuts Arq stock price target on GAC production pause2
ARQ Aktie jetzt für 0€ handeln
10.03.Arq outlines 2026 revenue and EBITDA guidance as GAC project paused for optimization3
10.03.Arq shares plunge 46% after weak earnings, disappointing 2026 outlook8
10.03.Morning Market Movers: MiNK Therapeutics, Garden Stage, Arq, Inc., SciSparc See Big Swings440BEIJING (dpa-AFX) - At 8:05 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening...
► Artikel lesen
10.03.Arq reports mixed Q4 results; provides inaugural financial guidance for FY264
10.03.Arq, Inc. Q4 Loss Increases4
09.03.Arq, Inc.: Arq Reports Fourth Quarter and Full Year 2025 Results874Generated record revenue of approximately $120 million for full-year 2025, driven by PAC performance Reported Adjusted EBITDA(1) of $13 million, representing 26% improvement year-over-year Provided...
► Artikel lesen
06.03.Arq Q4 2025 Earnings Preview3
06.03.Insights into Arq's Upcoming Earnings2
03.03.Arq, Inc. - 8-K, Current Report2
03.03.Arcutis enrolls first patient in ARQ-234 atopic dermatitis trial1
03.03.Arcutis Biotherapeutics, Inc.: Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis675Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitisARQ-234 is a potent fusion-protein...
► Artikel lesen
29.01.Arq, Inc. - 8-K, Current Report1
11.12.25Arq, Inc. - 8-K, Current Report-
10.12.25Arq (ARQ): Clear Street Reiterates Buy Rating3
06.11.25Arq Inc. verfehlt Q3-Prognosen: Aktie bricht nach enttäuschenden Zahlen ein3
05.11.25Arq, Inc.: Arq Reports Third Quarter 2025 Results193Generated revenue of $35 million, driven by strong performance of the foundational PAC business Reported Adjusted EBITDA of $5.2 million, achieving sixth consecutive quarter of positive Adjusted EBITDA...
► Artikel lesen
05.11.25Arq, Inc. - 8-K, Current Report-
05.11.25Arq, Inc. - 10-Q, Quarterly Report-
Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1